FindTrial
Sign In

to study the role of low dose heparin in cases of Stevens Johnson syndrome patients with chronic ocular complications

Role of Low dose heparin eye drops in chronic ocular cases of Steven Johnson Syndrome (SJS) and its correlation with immune pathway gene expression : A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019463
Enrollment
100
Registered
2019-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L511- Stevens-Johnson syndrome

Interventions

Intervention1: Low Dose Heparin drops: Low Dose Heparin drops (100 UI/ML) to be administered four times a day in acute cases and three times a day in chronic cases of SJS following a ocular wash. Cont

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed cases of SJS 2. Cases with no history of prior surgery for past six months 3. No active ocular surface infection.

Exclusion criteria

Exclusion criteria: 1. Patients below 8 years 2. History of surgical intervention in last six months 3. Cases with any systemic HIV infection 4. Pregnant or lactating SJS patients

Design outcomes

Primary

MeasureTime frame
1 Reduced severity scores for corneal complications post SJS 2 Improvement in Visual Acuity 3 Detection of NETs in SJS Timepoint: baseline- 0 month time point1 - 1 month—

Secondary

MeasureTime frame
1 Reduced severity scores for corneal complications post SJS 2 Improvement in Visual Acuity 3 Detection of NETs in SJSTimepoint: baseline - 0 month time point 1- 1 month—

Countries

India

Contacts

Public ContactDr Namrata Sharma

Dr. R. P.Centre for Ophthalmic Sciences, All India Institute of Medical Sciences

namrata.sharma@gmail.com01126593144

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026